VA-DXC-TECHNOLOGY
DXC Technology (NYSE: DXC) today introduced its Corporate Incident Response (CIR) application for ServiceNow to enable organizations like Banco Santander, one of the largest retail and commercial banks in the world, and the Nordex Group, one of the world’s largest wind turbine manufacturers, to quickly and proactively identify, address and manage important non-IT corporate incidents, such as those related to facilities, physical security, and environment, health and safety. The application, built on the ServiceNow platform, allows businesses to reduce their risk profiles and overcome situations before they evolve into companywide crises.
The CIR application provides an end-to-end workflow management solution to manage, track and respond to non-IT-related issues in an efficient, standardized manner.
“In today’s world, business disruptions are inevitable. While operational resilience has been around for years, a change in mindset is required in order to prevent, respond to, recover from, and most importantly, learn from and adapt after crises occur,” said Dan Stoks, vice president, Global ServiceNow Practice, DXC Technology. “The Corporate Incident Response application can work with ServiceNow’s integrated risk management and other workflows to enable organizations to securely manage crisis response workflows and risks to the business.”
Key features of the solution:
- Situation rooms — provide a central point of collaboration for dispersed organizations to orchestrate response teams and plans and monitor and evaluate the overall picture.
- App notifications — provide the ability to send companywide notifications, such as alerts, push notifications, email and SMS to predefined groups as well as external partners and customers.
- 360-degree view — provides the management team with a 360-degree view of where the organization stands on corporate-related incidents, so they can make fact-based decisions that reduce their overall risk profile.
Banco Santander Streamlines Crisis Management Systems with DXC CIR Application
Banco Santander wanted a single platform to manage its global facility and security processes and replace its previous system with a new, digitized platform. Using the DXC CIR application with ServiceNow, Santander streamlined its processes with better-performing facility, security and crisis management systems and improved user experiences for its managers and end users. It also benefited from better insights and greater transparency in its global facility and security services.
“The consolidation of existing and new facility management capabilities to a new platform was a crucial part of our business transformation journey,” said Galo Gilarranz Vicente, Real Estate, General Services and Security, Banco Santander. “DXC’s CIR application has allowed us to reduce costs by rationalizing the global application landscape, standardize our processes and increase employee efficiency with automation.”
The Nordex Group Improves Worker Safety with DXC’s Health, Safety and Environmental Management Business Expertise
The Nordex Group tapped the DXC Health, Safety and Environment Suite (HSE) for ServiceNow, which is part of DXC’s CIR portfolio, to create a safety-driven culture throughout its global operations. With the DXC suite, the Nordex Group experienced a more streamlined process to reduce worker hazards and prevent incidents before they occur.
“Nordex is committed to worker safety, implementing proper processes to prevent and quickly respond to work-related incidents,” said Philipp Marten, program manager, Business Systems, Nordex Group. “With DXC’s HSE solution, we were able to reduce the complexity of our system, streamline reporting and create a safer work environment throughout our global operations.”
DXC is offering this application for free for 120 days to complement and enhance the capabilities of ServiceNow Emergency Response Management applications.
“Operational risk management is a crucial part of how ServiceNow enables resilience for our customers for both IT and non-IT operations,” said David Parsons, senior vice president, Global Alliances and Channel Ecosystem, ServiceNow. “Corporate Incident Response from DXC Technology exemplifies the innovative applications that extend the value of the Now Platform and our Risk and Business Continuity portfolio to serve critical and emerging use cases for joint customers enterprise-wide.”
To learn more and download the CIR for ServiceNow application, click here .
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200521005190/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
